Novartis to build $92M cell and gene therapy plant in Stein, Switzerland

Novartis announced plans to construct a new cell and gene therapy production facility in Stein, Switzerland, with phased investments of approximately CHF 90 million ($92 million). The plant will support CAR-T drug Kymriah and create up to 450 jobs.

“Phased investments totalling approximately CHF 90 million [US$92 million] will be made over the next few years to support the new facility.”bioprocessintl.com

• 1 source
• bioprocessintl.comNovartis constructing $92m CAR-T plant as Kymriah arrives in EUDan StantonAug 28, 2018

Summarized from public sources; check the original articles before acting on it.